{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T22:50:07Z","timestamp":1777762207749,"version":"3.51.4"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceutical Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thrombosisresearch.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Thrombosis Research"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.thromres.2025.109402","type":"journal-article","created":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T10:35:27Z","timestamp":1752575727000},"page":"109402","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Real-world safety and effectiveness of rurioctocog alfa pegol in 338 patients with hemophilia A in South Korea: A postmarketing surveillance study"],"prefix":"10.1016","volume":"253","author":[{"given":"Ji Yoon","family":"Kim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taiju","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sang Kyu","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ki-Young","family":"Yoo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eun Jin","family":"Choi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soyon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chur Woo","family":"You","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eungsun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aeran","family":"Jung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Young-Shil","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.thromres.2025.109402_bb0005","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1016\/S0140-6736(11)61139-2","article-title":"Modern haemophilia care","volume":"379","author":"Berntorp","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.thromres.2025.109402_bb0010","series-title":"Hemophilia","author":"Mehta","year":"2024"},{"key":"10.1016\/j.thromres.2025.109402_bb0015","series-title":"GeneReviews\u00ae, Seattle (WA)","article-title":"Hemophilia A","author":"Konkle","year":"1993"},{"issue":"Suppl. 6","key":"10.1016\/j.thromres.2025.109402_bb0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/hae.14046","article-title":"WFH guidelines for the Management of Hemophilia panelists and co-authors, WFH guidelines for the management of hemophilia, 3rd edition","volume":"26","author":"Srivastava","year":"2020","journal-title":"Haemophilia"},{"key":"10.1016\/j.thromres.2025.109402_bb0025","doi-asserted-by":"crossref","DOI":"10.3346\/jkms.2020.35.e350","article-title":"Epidemiology of congenital bleeding disorders: a nationwide population-based Korean study","volume":"35","author":"Yoon","year":"2020","journal-title":"J. Korean Med. Sci."},{"key":"10.1016\/j.thromres.2025.109402_bb0030","series-title":"Annual Report","author":"Korean Haemophilia Foundation","year":"2023"},{"key":"10.1016\/j.thromres.2025.109402_bb0035","series-title":"Report on the Annual Global Survey","author":"World Federation of Hemophilia","year":"2022"},{"key":"10.1016\/j.thromres.2025.109402_bb0040","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41572-021-00278-x","article-title":"Haemophilia","volume":"7","author":"Berntorp","year":"2021","journal-title":"Nat. Rev. Dis. Primers."},{"key":"10.1016\/j.thromres.2025.109402_bb0045","first-page":"141","article-title":"Extended half-life coagulation factors: a new era in the management of hemophilia patients","volume":"36","author":"Ar","year":"2019","journal-title":"Turk. J. Haematol."},{"key":"10.1016\/j.thromres.2025.109402_bb0050","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1111\/hae.13438","article-title":"Defining extended half-life rFVIII-a critical review of the evidence","volume":"24","author":"Mahlangu","year":"2018","journal-title":"Haemophilia"},{"key":"10.1016\/j.thromres.2025.109402_bb0055","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1182\/blood-2015-03-630897","article-title":"Pegylated, full-length, recombinant factor VIII for prophylactic and on-demand treatment of severe hemophilia A","volume":"126","author":"Konkle","year":"2015","journal-title":"Blood"},{"issue":"Suppl. 1","key":"10.1016\/j.thromres.2025.109402_bb0060","first-page":"S29","article-title":"BAX 855, a PEGylated rFVIII product with prolonged half-life. Development, functional and structural characterisation","volume":"32","author":"Turecek","year":"2012","journal-title":"Hamostaseologie"},{"key":"10.1016\/j.thromres.2025.109402_bb0065","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1111\/hae.13119","article-title":"Extended half-life pegylated, full-length recombinant factor VIII for prophylaxis in children with severe haemophilia A","volume":"23","author":"Mullins","year":"2017","journal-title":"Haemophilia"},{"key":"10.1016\/j.thromres.2025.109402_bb0070","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1111\/hae.13970","article-title":"The Australian experience with switching to extended half-life factor VIII and IX concentrates: on behalf of the Australian Haemophilia Centre Directors\u2019 Organisation","volume":"26","author":"Brennan","year":"2020","journal-title":"Haemophilia"},{"key":"10.1016\/j.thromres.2025.109402_bb0075","doi-asserted-by":"crossref","first-page":"12967","DOI":"10.1038\/s41598-021-92245-5","article-title":"Bleeding outcomes and factor utilization after switching to an extended half-life product for prophylaxis in haemophilia A in Austria","volume":"11","author":"Ay","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.thromres.2025.109402_bb0080","first-page":"492","article-title":"A retrospective observational study of rurioctocog alfa pegol in clinical practice in the United States","volume":"26","author":"Aledort","year":"2020","journal-title":"J. Manag. Care Spec. Pharm."},{"key":"10.1016\/j.thromres.2025.109402_bb0085","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1182\/blood-2019-124101","article-title":"Real-world age-stratified FVIII consumption and bleed outcomes before and after switching to rurioctocog alfa pegol in a retrospective, observational study using US specialty pharmacy data","volume":"134","author":"Watt","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2025.109402_bb0090","author":"United States Food and Drug Administration (USFDA)"},{"key":"10.1016\/j.thromres.2025.109402_bb0095","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1080\/17474086.2023.2247160","article-title":"Immunogenicity, safety, and efficacy of rurioctocog alfa pegol in previously untreated patients with severe hemophilia A: interim results from a phase 3, prospective, multicenter, open-label study","volume":"16","author":"Sidonio","year":"2023","journal-title":"Expert Rev. Hematol."},{"key":"10.1016\/j.thromres.2025.109402_bb0100","author":"Ministry of Food and Drug Safety"},{"key":"10.1016\/j.thromres.2025.109402_bb0105","author":"European Medicines Agency (EMA)"},{"key":"10.1016\/j.thromres.2025.109402_bb0110","author":"Ministry of Food and Drug Safety"},{"key":"10.1016\/j.thromres.2025.109402_bb0115","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1111\/hae.13807","article-title":"Perioperative haemostasis with full-length, PEGylated, recombinant factor VIII with extended half-life (rurioctocog alfa pegol) in patients with haemophilia A: final results of a multicentre, single-arm phase III trial","volume":"25","author":"Gruppo","year":"2019","journal-title":"Haemophilia"},{"key":"10.1016\/j.thromres.2025.109402_bb0120","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1160\/TH16-06-0444","article-title":"Clinical evaluation of glycopegylated recombinant FVIII: efficacy and safety in severe haemophilia A","volume":"117","author":"Giangrande","year":"2017","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.thromres.2025.109402_bb0125","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1160\/TH17-03-0166","article-title":"Safety and efficacy of a glycopegylated rFVIII (turoctocog alpha pegol, N8-GP) in paediatric patients with severe haemophilia A","volume":"117","author":"Meunier","year":"2017","journal-title":"Thromb. Haemost."},{"issue":"Suppl. 1","key":"10.1016\/j.thromres.2025.109402_bb0130","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/jth.15036","article-title":"Long-term safety and efficacy of N8-GP in previously treated pediatric patients with hemophilia A: final results from pathfinder5","volume":"18","author":"\u0160aulyt\u0117 Trakymien\u0117","year":"2020","journal-title":"J. Thromb. Haemost."},{"issue":"Suppl. 1","key":"10.1016\/j.thromres.2025.109402_bb0135","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/jth.14959","article-title":"Long-term safety and efficacy of N8-GP in previously treated adults and adolescents with hemophilia A: final results from pathfinder2","volume":"18","author":"Giangrande","year":"2020","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.thromres.2025.109402_bb0140","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/jth.13597","article-title":"Safety and efficacy of BAY 94-9027, a prolonged-half-life factor VIII","volume":"15","author":"Reding","year":"2017","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.thromres.2025.109402_bb0145","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1111\/hae.13853","article-title":"BAY 94-9027 prophylaxis is efficacious and well tolerated for up to >5 years with extended dosing intervals: PROTECT VIII extension interim results","volume":"25","author":"Lalezari","year":"2019","journal-title":"Haemophilia"},{"key":"10.1016\/j.thromres.2025.109402_bb0150","doi-asserted-by":"crossref","first-page":"e347","DOI":"10.1111\/hae.14297","article-title":"Confirmed long-term safety and efficacy of prophylactic treatment with BAY 94-9027 in severe haemophilia A: final results of the PROTECT VIII extension study","volume":"27","author":"Reding","year":"2021","journal-title":"Haemophilia"},{"key":"10.1016\/j.thromres.2025.109402_bb0155","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1111\/jth.13647","article-title":"Safety, efficacy and pharmacokinetics of rVIII-SingleChain in children with severe hemophilia A: results of a multicenter clinical trial","volume":"15","author":"Stasyshyn","year":"2017","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.thromres.2025.109402_bb0160","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1007\/s12185-018-02574-x","article-title":"Inhibitor development, safety and efficacy of Advate\u00ae among previously treated patients with hemophilia A in a postmarketing surveillance in Japan","volume":"109","author":"Fukutake","year":"2019","journal-title":"Int. J. Hematol."},{"key":"10.1016\/j.thromres.2025.109402_bb0165","doi-asserted-by":"crossref","first-page":"e168","DOI":"10.1111\/hae.14052","article-title":"Long-term safety and efficacy results from the phase 3b, open-label, multicentre Continuation study of rurioctocog alfa pegol for prophylaxis in previously treated patients with severe haemophilia A","volume":"26","author":"Chowdary","year":"2020","journal-title":"Haemophilia"},{"key":"10.1016\/j.thromres.2025.109402_bb0170","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1007\/s12185-017-2265-6","article-title":"Efficacy and safety of full-length pegylated recombinant factor VIII with extended half-life in previously treated patients with hemophilia A: comparison of data between the general and Japanese study populations","volume":"106","author":"Nogami","year":"2017","journal-title":"Int. J. Hematol."},{"key":"10.1016\/j.thromres.2025.109402_bb0175","doi-asserted-by":"crossref","first-page":"198","DOI":"10.5045\/br.2019.54.3.198","article-title":"Subgroup analysis of a phase 2\/3 study of rurioctocog alfa pegol in patients with severe hemophilia A: efficacy and safety in previously treated Korean patients","volume":"54","author":"You","year":"2019","journal-title":"Blood Res."},{"key":"10.1016\/j.thromres.2025.109402_bb0180","doi-asserted-by":"crossref","first-page":"e281","DOI":"10.1111\/hae.12647","article-title":"Allergic reaction in a cohort of haemophilia A patients using plasma-derived factor VIII (FVIII) concentrate is rare and not necessarily triggered by FVIII","volume":"21","author":"Montalv\u00e3o","year":"2015","journal-title":"Haemophilia"},{"issue":"2017","key":"10.1016\/j.thromres.2025.109402_bb0185","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.2147\/PPA.S139851","article-title":"Treatment adherence in hemophilia","volume":"11","author":"Thornburg","year":"2017","journal-title":"Patient Prefer. Adherence"},{"key":"10.1016\/j.thromres.2025.109402_bb0190","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1182\/blood-2020-138898","article-title":"Dosing, patient satisfaction and other patient-reported outcomes after switching to rurioctocog alfa pegol in Athn 2: a longitudinal, observational study of previously treated hemophilia patients switching coagulation replacement factor products [abstract]","volume":"136","author":"Journeycake","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2025.109402_bb0195","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1111\/hae.14304","article-title":"Patients' and parents' satisfaction with, and preference for, haemophilia A treatments: a cross-sectional, multicentre, observational study","volume":"27","author":"Park","year":"2021","journal-title":"Haemophilia"},{"key":"10.1016\/j.thromres.2025.109402_bb0200","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1248\/bpb.b13-00661","article-title":"Discussion about several potential drawbacks of PEGylated therapeutic proteins","volume":"37","author":"Zhang","year":"2014","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.thromres.2025.109402_bb0205","doi-asserted-by":"crossref","first-page":"75","DOI":"10.3390\/ph11030075","article-title":"Polyethylene glycol exposure with antihemophilic factor (recombinant), PEGylated (Rurioctocog alfa pegol) and other therapies indicated for the pediatric population: history and safety","volume":"11","author":"Stidl","year":"2018","journal-title":"Pharmaceuticals (Basel, Switzerland)"},{"key":"10.1016\/j.thromres.2025.109402_bb0210","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1182\/asheducation-2016.1.657","article-title":"Hemophilia and inhibitors: current treatment options and potential new therapeutic approaches","volume":"2016","author":"Meeks","year":"2016","journal-title":"Hematology Am. Soc. Hematol. Educ. Program"},{"key":"10.1016\/j.thromres.2025.109402_bb0215","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2023.101164","article-title":"Nothing short of a revolution: novel extended half-life factor VIII replacement products and non-replacement agents reshape the treatment landscape in hemophilia A","volume":"64","author":"Abdelgawad","year":"2024","journal-title":"Blood Rev."},{"key":"10.1016\/j.thromres.2025.109402_bb0220","doi-asserted-by":"crossref","first-page":"2726","DOI":"10.1182\/bloodadvances.2023011780","article-title":"Immunogenicity profile of rurioctocog alfa pegol in previously treated patients with severe congenital hemophilia A","volume":"8","author":"Horling","year":"2024","journal-title":"Blood Adv."}],"updated-by":[{"DOI":"10.1016\/j.thromres.2026.109586","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T00:00:00Z","timestamp":1769731200000}},{"DOI":"10.1016\/j.thromres.2026.109586","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000}}],"container-title":["Thrombosis Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384825001525?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384825001525?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T14:26:37Z","timestamp":1777472797000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049384825001525"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":44,"alternative-id":["S0049384825001525"],"URL":"https:\/\/doi.org\/10.1016\/j.thromres.2025.109402","relation":{},"ISSN":["0049-3848"],"issn-type":[{"value":"0049-3848","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world safety and effectiveness of rurioctocog alfa pegol in 338 patients with hemophilia A in South Korea: A postmarketing surveillance study","name":"articletitle","label":"Article Title"},{"value":"Thrombosis Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.thromres.2025.109402","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Takeda Pharmaceuticals Korea Co., Ltd. Published by Elsevier Ltd","name":"copyright","label":"Copyright"}],"article-number":"109402"}}